| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02022982 | KRAS Mutant Non-Small Cell Lung Cancer|Solid Tumors | Drug: Palbociclib|Drug: PD-0325901 | Dana-Farber Cancer Institute | Phase 1|Phase 2 | 2014-01-01 | 2016-12-15 |
| NCT02096471 | Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN | Drug: PD-0325901 | University of Alabama at Birmingham | Phase 2 | 2014-06-01 | 2016-12-14 |
| NCT00174369 | Carcinoma, Non-Small-Cell Lung | Drug: PD-0325901 | Pfizer | Phase 2 | 2005-11-01 | 2009-03-16 |
| NCT02297802 | Prior Treatment With PD-0325901 With Ongoing Clinical Response | Drug: PD-0325901 | Sharp HealthCare | Phase 1 | 2013-06-01 | 2014-11-24 |
| NCT02039336 | Colorectal Cancer | Drug: Dacomitinib|Drug: PD-0325901|Drug: Irinotecan|Drug: Docetaxel|Drug: Capecitabine | The Netherlands Cancer Institute|Pfizer | Phase 1|Phase 2 | 2014-01-01 | 2016-11-10 |
| NCT00147550 | Melanoma|Colonic Neoplasms|Breast Neoplasms | Drug: PD-0325901 | Pfizer | Phase 1|Phase 2 | 2004-02-01 | 2013-09-11 |
| NCT02510001 | Solid Tumour|Colorectal Cancer | Drug: PF-02341066|Drug: PD-0325901|Drug: Binimetinib | University of Oxford|Queen's University, Belfast|Oxford University Hospitals NHS Trust|Velindre NHS Trust|University Hospital, Antwerp|Hospital Vall d'Hebron|Hopital St Antoine, Paris|European Georges Pompidou Hospital|Pfizer|University of Turin, Italy|Belfast Health and Social Care Trust|Beaumont Hospital|European Commission|Array BioPharma|Q2 solutions|Covance|QPS Holdings | Phase 1 | 2014-11-01 | 2016-08-31 |
| NCT01347866 | Advanced Cancer | Drug: PF-05212384|Drug: PD-0325901|Drug: PF-05212384|Drug: irinotecan | Pfizer | Phase 1 | 2011-10-01 | 2016-01-13 |
